Table 1.

Summary of the clinical and molecular characteristics for the study cohort

Sex (n = 150), n (%)
 Male, 100 (67)
 Female, 50 (33)
Age (n = 145), y
 Median, 64
 Range, 45–87
Site of primary (n = 129), n (%)
 Colon, 100 (78)
 Rectum, 29 (22)
Diagnosis (n = 128), n (%)
 Synchronous, 69 (54)
 Metachronous, 59 (46)
Previous chemotherapy (n = 128), n (%)
 Yes, 46 (36)
 No, 81 (64)
Neoadjuvant (n = 128), n (%)
 Yes, 76 (61)
 No, 48 (39)
KRAS status (n = 139), n (%)
 Codon 12, 40 (29)
 Codon 61, 1 (0.7)
 Codon 13, 10 (7.2)
 Codon 146, 4 (2.9)
BRAF status (n = 138), n (%)
 Codon 600, 3 (2.2)
NRAS status (n = 138), n (%)
 Codon 12, 2 (1.4)
 Codon 61, 6 (4.3)
PIK3CA status (n = 138), n (%)
 Codon 545, 5 (3.6)
 Codon 546, 1 (0.7)
 Codon 1047, 7 (5)